BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18752867)

  • 1. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
    Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
    Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice.
    Cui R; Yoshioka M; Takahashi F; Ishida H; Iwakami S; Takahashi K
    Anticancer Res; 2008; 28(3A):1633-9. PubMed ID: 18630520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha promotes malignant pleural effusion.
    Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
    Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
    Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
    Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
    Wang ZM; Cui YH; Li W; Chen SY; Liu TS
    Oncol Rep; 2011 Apr; 25(4):997-1003. PubMed ID: 21286666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
    Gong M; Lu Z; Fang G; Bi J; Xue X
    Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of osteopontin would suppress angiogenesis in gastric cancer.
    Tang H; Wang J; Bai F; Hong L; Liang J; Gao J; Zhai H; Lan M; Zhang F; Wu K; Fan D
    Biochem Cell Biol; 2007 Feb; 85(1):103-10. PubMed ID: 17464350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer.
    Du XL; Jiang T; Sheng XG; Gao R; Li QS
    Gynecol Oncol; 2009 Dec; 115(3):371-6. PubMed ID: 19783287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
    J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
    Gu T; Ohashi R; Cui R; Tajima K; Yoshioka M; Iwakami S; Sasaki S; Shinohara A; Matsukawa T; Kobayashi J; Inaba Y; Takahashi K
    Lung Cancer; 2009 Nov; 66(2):176-83. PubMed ID: 19285749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
    Ishii H; Yazawa T; Sato H; Suzuki T; Ikeda M; Hayashi Y; Takanashi Y; Kitamura H
    Lung Cancer; 2004 Sep; 45(3):325-37. PubMed ID: 15301873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
    Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
    Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
    Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
    Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof].
    Gui SY; Li HH; Zuo L; Zhou Q; Wu Q; Wang Y
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3219-23. PubMed ID: 18399118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells.
    Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L
    Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.
    Wai PY; Mi Z; Guo H; Sarraf-Yazdi S; Gao C; Wei J; Marroquin CE; Clary B; Kuo PC
    Carcinogenesis; 2005 Apr; 26(4):741-51. PubMed ID: 15661802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
    Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
    Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
    Dai J; Peng L; Fan K; Wang H; Wei R; Ji G; Cai J; Lu B; Li B; Zhang D; Kang Y; Tan M; Qian W; Guo Y
    Oncogene; 2009 Sep; 28(38):3412-22. PubMed ID: 19597469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.